Optimi Health Completes Production Batch Of 5mg Naturally Derived Psilocybin Capsules, Manufactured End To End At cGMP Facility In Princeton, British Columbia

Optimi Health Corp. has completed a production batch of 5mg naturally derived psilocybin capsules at its cGMP facility in Princeton, British Columbia, authorized by Health Canada. This batch will support a Phase 2 clinical trial for psilocybin-assisted therapy in treating major depressive disorder, involving up to 200 participants, with dosing expected to conclude by the end of 2027. Additionally, the capsules will be supplied to licensed clinics in Australia for patients with treatment-resistant depression, with reimbursement options available from various public and private payers.